Moberg Pharma AB (publ) (STO:MOB)

Sweden flag Sweden · Delayed Price · Currency is SEK
10.35
+0.32 (3.19%)
At close: Feb 27, 2026
13.18%
Market Cap 486.46M
Revenue (ttm) 13.54M
Net Income (ttm) -27.24M
Shares Out 47.00M
EPS (ttm) -0.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 116,215
Average Volume 72,632
Open 9.94
Previous Close 10.03
Day's Range 9.80 - 10.35
52-Week Range 6.52 - 12.10
Beta 1.15
RSI 70.22
Earnings Date Feb 17, 2026

About Moberg Pharma AB

Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden. [Read more]

Sector Healthcare
Founded 2006
Employees 5
Stock Exchange Nasdaq Stockholm
Ticker Symbol MOB
Full Company Profile

Financial Performance

In 2025, Moberg Pharma AB's revenue was 13.54 million, an increase of 37.99% compared to the previous year's 9.81 million. Losses were -27.24 million, -89.32% less than in 2024.

Financial Statements

News

There is no news available yet.